Jenscare Scientific's (HKG:9877) LuX-Valve Plus transvenous tricuspid valve replacement system has received approval from Hong Kong's Department of Health, according to a Friday Hong Kong bourse filing.
The medical device company plans to commercialize the device in Hong Kong, while LuX-Valve Plus has already obtained regulatory approvals in countries and regions across Europe, the Middle East and Asia-Pacific, the filing said.
Shares of the company fell over 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.